Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus CIPRODEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus CIPRODEX.
CHLOROMYXIN vs CIPRODEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, blocking bacterial DNA replication; dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension: 4 drops into affected ear(s) twice daily for 7 days.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
Ciprofloxacin: terminal elimination half-life 3-5 hours (prolonged to 5-10 hours in renal impairment). Dexamethasone: biological half-life 36-54 hours.
CHLOROMYXIN is not a recognized drug. No data available.
Ciprofloxacin: 50-70% renal (glomerular filtration and tubular secretion), 20-35% biliary/fecal. Dexamethasone: renal elimination of metabolites, <5% unchanged.
Category C
Category C
Antibiotic
Antibiotic/Corticosteroid Combination (Otic)